ZZPZH(SH:600436) Di Yi Cai Jing·2025-10-21 11:29Core Viewpoint - The price of Pianzaihuang pills, known as "the Maotai of medicine," has decreased, with retail prices on e-commerce platforms falling below the official price of 760 yuan per pill, even dropping to around 600 yuan [2][9]. Financial Performance - In the first three quarters of this year, Pianzaihuang reported a revenue of 7.442 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 2.129 billion yuan, down 20.74% year-on-year [4]. - The decline in net profit in the first three quarters exceeded the 16.22% drop observed in the first half of the year [4]. - The main reason for the performance decline is attributed to reduced sales in the pharmaceutical manufacturing sector and a decrease in gross profit margin [4]. Product Performance - The pharmaceutical manufacturing segment generated a revenue of 4.016 billion yuan, down 12.93% year-on-year, with the liver disease medication segment, which includes Pianzaihuang pills, contributing 3.88 billion yuan, a decrease of 9.41% [4]. - The gross profit margin for the liver disease medication segment has dropped from over 81% before 2023 to 61.11% in the first three quarters of this year, a decrease of 9.68 percentage points [9]. Market Dynamics - The sales of Pianzaihuang pills are closely linked to the company's overall performance, and the current market conditions have led to a cooling in sales [4][10]. - The company has faced challenges in expanding its market presence beyond its traditional stronghold in Fujian, with insufficient investment in nationwide distribution channels [10]. - The timing of the price increase in May 2023 was not ideal, as the market was already showing signs of cooling, which negatively impacted sales [10]. Inventory Concerns - The company's inventory has increased, with the total amount reaching 6.16 billion yuan by the end of the third quarter, up 34.9% from 4.566 billion yuan in the same period last year [11].